Therapeutic targeting of altered airway microbiota to prevent lung damage and pneumonia in mice with cystic fibrosis-like lung disease (B08*)

在囊性纤维化（CF）患者中，气道微生物群的改变与肺部疾病的严重程度相关。然而，紊乱的微生物群在体内发病机制中的作用以及作为CF肺病的治疗靶点仍然未知。因此，在该项目中，我们将使用独特的CF肺病小鼠模型和最先进的下一代测序技术i）确定改变的气道微生物群在CF样气道炎症和结构性肺损伤中的作用; ii）测试异常微生物群的治疗靶向是否可以减少这些异常;和iii）测试这种治疗方法是否可以在体内降低对CF肺病特征性的铜绿假单胞菌感染的易感性。

Alterations in airway microbiota are associated with severity of lung disease in patients with cystic fibrosis (CF). However, the role of disordered microbiota in the in vivo pathogenesis and as therapeutic target in CF lung disease remains unknown. In this project, we will therefore use a unique mouse model of CF lung disease and state-of-the-art next generation sequencing i) to determine the role of altered airway microbiota in CF-like airway inflammation and structural lung damage; ii) to test if therapeutic targeting of abnormal microbiota can reduce these abnormalities; and iii) to test if such a therapeutic approach can reduce susceptibility to Pseudomonas aeruginosa infection characteristic of CF lung disease in vivo.